Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA
Introduction Based on data from the DESTINY-Breast03 trial, we performed a cost-effectiveness analysis of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had been previously treated with trastuzumab and a taxane from the US payer perspective. Methods We conducted a Markov model to assess the cost-effectiveness of T-DXd versus trastuzumab emtansine (T-DM1). The simulation time horizon for this model was the lifetime of patients. Transition probabilities were based on data from the DESTINY-Breast03 trial. Health utility data were derived from published studies. Outcome measures were costs (in 2022 US$), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses assessed the uncertainty of key model parameters and their joint impact on the base-case results. Results The base-case results found that T-DXd provided an improvement of 3.90 QALYs compared with T-DM1, and the ICER was $220,533 per QALY. The one-way sensitivity analysis demonstrated that the utility value of progression-free survival, hazard ratios of T-Dxd versus T-DM1, and cost of T-Dxd contributed substantial uncertainty to the model. Probabilistic sensitivity analysis predicted T-DXd being cost-effective compared to T-DM1 was 0, 1, 16, and 46% at willingness-to-pay of $50,000, $100,000, $150,000, and 200,000 per QALY, respectively. Conclusion T-DXd was unlikely to offer a reasonable value for the money spent compared to T-DM1 in a US payer setting..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
---|---|
Enthalten in: |
Advances in therapy - 39(2022), 10 vom: 09. Aug., Seite 4583-4593 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Jingyan [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Breast cancer |
Anmerkungen: |
© The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1007/s12325-022-02273-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2079510096 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2079510096 | ||
003 | DE-627 | ||
005 | 20230514122454.0 | ||
007 | tu | ||
008 | 221220s2022 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s12325-022-02273-4 |2 doi | |
035 | |a (DE-627)OLC2079510096 | ||
035 | |a (DE-He213)s12325-022-02273-4-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.40$jPharmazie$jPharmazeutika |2 bkl | ||
100 | 1 | |a Wang, Jingyan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Introduction Based on data from the DESTINY-Breast03 trial, we performed a cost-effectiveness analysis of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had been previously treated with trastuzumab and a taxane from the US payer perspective. Methods We conducted a Markov model to assess the cost-effectiveness of T-DXd versus trastuzumab emtansine (T-DM1). The simulation time horizon for this model was the lifetime of patients. Transition probabilities were based on data from the DESTINY-Breast03 trial. Health utility data were derived from published studies. Outcome measures were costs (in 2022 US$), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses assessed the uncertainty of key model parameters and their joint impact on the base-case results. Results The base-case results found that T-DXd provided an improvement of 3.90 QALYs compared with T-DM1, and the ICER was $220,533 per QALY. The one-way sensitivity analysis demonstrated that the utility value of progression-free survival, hazard ratios of T-Dxd versus T-DM1, and cost of T-Dxd contributed substantial uncertainty to the model. Probabilistic sensitivity analysis predicted T-DXd being cost-effective compared to T-DM1 was 0, 1, 16, and 46% at willingness-to-pay of $50,000, $100,000, $150,000, and 200,000 per QALY, respectively. Conclusion T-DXd was unlikely to offer a reasonable value for the money spent compared to T-DM1 in a US payer setting. | ||
650 | 4 | |a Breast cancer | |
650 | 4 | |a Cost-effectiveness | |
650 | 4 | |a Markov model | |
650 | 4 | |a Trastuzumab deruxtecan | |
650 | 4 | |a Trastuzumab emtansine | |
700 | 1 | |a Yi, Yinzhi |4 aut | |
700 | 1 | |a Wan, Xiaomin |4 aut | |
700 | 1 | |a Zeng, Xiaohui |4 aut | |
700 | 1 | |a Peng, Ye |4 aut | |
700 | 1 | |a Tan, Chongqing |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Springer Healthcare, 1984 |g 39(2022), 10 vom: 09. Aug., Seite 4583-4593 |w (DE-627)168085585 |w (DE-600)632651-1 |w (DE-576)482252200 |x 0741-238X |7 nnns |
773 | 1 | 8 | |g volume:39 |g year:2022 |g number:10 |g day:09 |g month:08 |g pages:4583-4593 |
856 | 4 | 1 | |u https://doi.org/10.1007/s12325-022-02273-4 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
936 | b | k | |a 44.40$jPharmazie$jPharmazeutika |q VZ |0 106423304 |0 (DE-625)106423304 |
951 | |a AR | ||
952 | |d 39 |j 2022 |e 10 |b 09 |c 08 |h 4583-4593 |